实用心脑肺血管病杂志
實用心腦肺血管病雜誌
실용심뇌폐혈관병잡지
PRACTICAL JOURNAL OF CARDIAC CEREBRAL PNEUMAL AND VASCULAR DISEASE
2014年
9期
18-19
,共2页
奥拉西坦%痴呆,血管性%治疗结果
奧拉西坦%癡呆,血管性%治療結果
오랍서탄%치태,혈관성%치료결과
Oxiracetam%Dementia,vascular%Treatment outcome
目的：观察奥拉西坦（欧兰同）治疗血管性痴呆（VD）的临床疗效。方法选择2013年青岛市市立医院干部保健科收治的 VD 住院患者75例，将其随机分为治疗组38例和对照组37例。对照组患者给予吡拉西坦治疗，治疗组患者给予奥拉西坦治疗，两组均以21 d 为1个疗程。统计两组患者治疗前、治疗14 d 及21 d 后简易精神状态评价量表（MMSE）[4]和长谷川痴呆量表（HDS）评分；评定治疗后两组临床疗效及观察治疗期间不良反应情况。结果治疗前和治疗14 d 后两组患者 MMSE 评分和 HDS 评分比较，差异均无统计学意义（ P ﹥0.05）；治疗21 d 后对照组MMSE 评分为（18.13±2.66）分、HDS 评分为（18.31±3.75）分，均低于治疗组的（19.65±3.45）分、（20.94±3.79）分（P ﹤0.05）。治疗组有效率为86.8%，高于对照组的67.6%（P ﹤0.05）；不良反应发生率为5.3%，与对照组的13.5%比较，差异无统计学意义（P ﹥0.05）。结论奥拉西坦治疗 VD 疗效显著，能有效提高患者智力，控制和减轻痴呆程度，且未增加不良反应的发生。
目的：觀察奧拉西坦（歐蘭同）治療血管性癡呆（VD）的臨床療效。方法選擇2013年青島市市立醫院榦部保健科收治的 VD 住院患者75例，將其隨機分為治療組38例和對照組37例。對照組患者給予吡拉西坦治療，治療組患者給予奧拉西坦治療，兩組均以21 d 為1箇療程。統計兩組患者治療前、治療14 d 及21 d 後簡易精神狀態評價量錶（MMSE）[4]和長穀川癡呆量錶（HDS）評分；評定治療後兩組臨床療效及觀察治療期間不良反應情況。結果治療前和治療14 d 後兩組患者 MMSE 評分和 HDS 評分比較，差異均無統計學意義（ P ﹥0.05）；治療21 d 後對照組MMSE 評分為（18.13±2.66）分、HDS 評分為（18.31±3.75）分，均低于治療組的（19.65±3.45）分、（20.94±3.79）分（P ﹤0.05）。治療組有效率為86.8%，高于對照組的67.6%（P ﹤0.05）；不良反應髮生率為5.3%，與對照組的13.5%比較，差異無統計學意義（P ﹥0.05）。結論奧拉西坦治療 VD 療效顯著，能有效提高患者智力，控製和減輕癡呆程度，且未增加不良反應的髮生。
목적：관찰오랍서탄（구란동）치료혈관성치태（VD）적림상료효。방법선택2013년청도시시립의원간부보건과수치적 VD 주원환자75례，장기수궤분위치료조38례화대조조37례。대조조환자급여필랍서탄치료，치료조환자급여오랍서탄치료，량조균이21 d 위1개료정。통계량조환자치료전、치료14 d 급21 d 후간역정신상태평개량표（MMSE）[4]화장곡천치태량표（HDS）평분；평정치료후량조림상료효급관찰치료기간불량반응정황。결과치료전화치료14 d 후량조환자 MMSE 평분화 HDS 평분비교，차이균무통계학의의（ P ﹥0.05）；치료21 d 후대조조MMSE 평분위（18.13±2.66）분、HDS 평분위（18.31±3.75）분，균저우치료조적（19.65±3.45）분、（20.94±3.79）분（P ﹤0.05）。치료조유효솔위86.8%，고우대조조적67.6%（P ﹤0.05）；불량반응발생솔위5.3%，여대조조적13.5%비교，차이무통계학의의（P ﹥0.05）。결론오랍서탄치료 VD 료효현저，능유효제고환자지력，공제화감경치태정도，차미증가불량반응적발생。
Objective To investigate the clinical effect of oxiracetam on vascular dementia( VD). Methods In 2013,75 patients with VD admitted to Department of Cadres Health Care,Qingdao Municipal Hospital,were selected and ran-domly divided into the treatment group(n = 38)and control group(n = 37). Control group given piracetam,treatment group given oxiracetam,both groups treated for 21 days. The scores of MMSE and HDS of the two groups before and after treatment were counted;the clinical effect after treatment and adverse reactions during treatment were observed. Results There was no signifi-cant differences of scores of MMSE and HDS between the two groups before treatment and 14 days after treatment(P ﹥ 0. 05);21 days after treatment,MMSE score and HDS score of control group was(18. 13 ± 2. 66),(18. 31 ± 3. 75),respectively, was lower than that of treatment group of(19. 65 ± 3. 45),(20. 94 ± 3. 79),respectively(P ﹤ 0. 05). The effective rate of treatment group was 86. 8% ,was higher than that of control group of 67. 6% (P ﹤ 0. 05);the incidence of adverse reactions of treatment group was 5. 3% ,that of control group was 13. 5% ,the difference was not statistically significant(P ﹥ 0. 05). Con-clusion Oxiracetam has a certain effect on VD,which can effectively improve patients'mentality,control and mitigate the de-gree of dementia,and is with fewer adverse reactions.
